• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    (OP:SDZNY)

    83.36 -3.36 (-3.88%)
    Streaming Delayed Price Updated: 11:48 AM EST, Mar 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 48,410
    Open 82.40
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 86.72
    Today's Range 81.51 - 83.74
    52wk Range 35.61 - 94.15
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
    As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
    Via Finterra
    Topics Economy Initial Public Offering Retirement
    News headline image
    Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
    As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its... 
    Via MarketMinute
    Topics Artificial Intelligence Bankruptcy Economy

    Performance

    YTD
    +14.2%
    +14.2%
    1 Month
    +5.8%
    +5.8%
    3 Month
    +18.3%
    +18.3%
    6 Month
    +35.6%
    +35.6%
    1 Year
    +88.8%
    +88.8%

    More News

    Read More
    News headline image
    Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
    From Sandoz
    Via Business Wire
    News headline image
    Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor ↗
    Via Benzinga
    Topics Intellectual Property
    News headline image
    Life Sciences Investor Forum: Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Life Sciences Investor Forum Agenda Announced for June 11th-12th
    From Virtual Investor Conferences
    Via GlobeNewswire
    News headline image
    Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug ↗
    Via Benzinga
    Topics Intellectual Property Lawsuit
    News headline image
    [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz reports strong FY 2024 results and Q4 2024 sales
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗
    Via Benzinga
    News headline image
    Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Francisco Ballester to retire; Peter Stenico appointed President Region International
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
    From Sandoz Group
    Via GlobeNewswire
    News headline image
    Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
    From Sandoz Group
    Via GlobeNewswire

    Frequently Asked Questions

    Is SDZNY publicly traded?
    Yes, SDZNY is publicly traded.
    What exchange does SDZNY trade on?
    SDZNY trades on the OTC Traded
    What is the ticker symbol for SDZNY?
    The ticker symbol for SDZNY is SDZNY on the OTC Traded
    What is the current price of SDZNY?
    The current price of SDZNY is 83.36
    When was SDZNY last traded?
    The last trade of SDZNY was at 03/03/26 11:48 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.